1	MET receptor activation by stromal cells serves as promising target
2	in melanoma brain metastases
3	
4	Torben Redmer <sup>1,2,*</sup> , Elisa Schumann <sup>3,4</sup> , Kristin Peters <sup>5</sup> , Martin E. Weidemeier <sup>6</sup> , Stephan
5	Nowak <sup>6</sup> , Henry W.S. Schroeder <sup>6</sup> , Anna Vidal <sup>1</sup> , Helena Radbruch <sup>3</sup> , Annika Lehmann <sup>7</sup> ,
6	Susanne Kreuzer-Redmer <sup>8</sup> , Karsten Jürchott <sup>9</sup> , Josefine Radke <sup>5,*</sup>
7	
8	*corresponding authors
9	Torben Redmer
10	Email: torben.redmer@vetmeduni.ac.at
11	Josefine Radke
12	Email: josefine.radke@med.uni-greifswald.de
13 14	<sup>1</sup> Institute for Medical Biochemistry, University of Veterinary Medicine Vienna, Vienna, Austria
15	<sup>2</sup> Institute of Pathology, Unit of Laboratory Animal Pathology, University of Veterinary
16	Medicine Vienna, Veterinärplatz 1, Vienna, Austria
17	<sup>3</sup> Department of Neuropathology, Charité-Universitätsmedizin Berlin, corporate member of
18	Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin,
19	Germany
20	<sup>4</sup> German Cancer Consortium (DKTK), Partner Site Berlin, CCCC (Campus Mitte), Berlin,
21	Germany
22	<sup>5</sup> Institute of Pathology, University Medicine Greifswald, Greifswald, Germany
23	<sup>6</sup> Department of Neurosurgery, University Medicine Greifswald, Greifswald, Germany
24	<sup>7</sup> Institute of Pathology, Charité-Universitätsmedizin Berlin, corporate member of Freie
25	Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin,
26	Germany
27	<sup>8</sup> Nutrigenomics Unit, Institute of Animal Nutrition and Functional Plant Compounds,
28	University of Veterinary Medicine Vienna, Vienna, Austria

#### 54 Abstract

55 The development of brain metastases hallmarks disease progression in 20-40% of 56 melanoma patients and is a serious obstacle to therapy. Understanding the processes 57 involved in the development and maintenance of melanoma brain metastases (MBM) is 58 critical for the discovery of novel therapeutic strategies. Here, we generated transcriptome 59 and methylome profiles of MBM showing high or low abundance of infiltrated Iba1<sup>high</sup> tumor-60 associated microglia and macrophages (TAMs). Our survey identified potential prognostic 61 markers of favorable disease course and response to immune checkpoint inhibitor (ICi) 62 therapy, among them APBB1IP and the interferon-responsive gene ITGB7. In MBM with high 63 ITGB7/APBB1IP levels, the accumulation of TAMs correlated significantly with the immune 64 score. Signature-based deconvolution of MBM via single sample GSEA revealed enrichment 65 of interferon-response and immune signatures and revealed inflammation, stress and MET 66 receptor signaling. MET receptor phosphorylation/activation maybe elicited by inflammatory 67 processes in brain metastatic melanoma cells via stroma cell-released HGF. We observed 68 phospho-MET<sup>Y1234/1235</sup> in a subset of MBM and observed marked response of brain 69 metastasis-derived cell lines (BMCs) that lacked druggable BRAF mutations or developed 70 resistance to BRAF inhibitors (BRAFi) in vivo to MET inhibitors PHA-665752 and ARQ197 71 (tivantinib). In summary, the activation of MET receptor in brain colonizing melanoma cells by 72 stromal cell-released HGF may promote tumor cells self-maintenance and expansion might 73 counteract ICi therapy. Therefore, therapeutic targeting of MET possibly serves as promising 74 strategy to control intracranial progressive disease and improve patient survival.

75

Key words: Melanoma, brain metastasis, TAMs, interferon signaling, MET receptor

- 76
- 77

78

79

## 80 Introduction

81 The interaction of brain colonizing tumor cells with the tumor microenvironment (TME), 82 mainly comprising innate and adaptive immune cells, microglia, astrocytes, neurons and 83 oligodendrocytes crucially determines the developmental stages of brain metastases (BM). 84 Brain metastases are observed in 20 - 40% of melanoma patients during the course of 85 disease and micrometastases are evident in more than 75% of autopsied brains<sup>1</sup>. Hence, 86 only a subset of melanoma cells that entered the brain develop symptomatic and detectable 87 BM during the lifetime of melanoma patients. Unlike peripheral metastases, the emergence 88 of BM depends on a plethora of environmental cues such as the spatiotemporal availability of 89 factors that are provided by cells of the TME, supporting or repressing tumor cell growth<sup>2</sup>. 90 Moreover, single-cell RNA sequencing (scRNAseq) studies have confirmed regional heterogeneity of astrocytes<sup>3</sup>, oligodendrocytes<sup>4</sup> and microglia<sup>5,6</sup> in healthy human brains. 91 Particularly, astrocytes and microglia adopt a reactive cell state<sup>7,8</sup> that accompanies 92 secretion of pro- and anti-inflammatory factors under pathological conditions<sup>9,10</sup>. It is 93 94 therefore possible that subfractions of astrocytes and microglia communicate and react with 95 tumor cells in different ways. Probably, neuroinflammation precedes colonization of the brain 96 by tumor cells. However, tumor cells invading the brain amplify inflammatory processes 97 mediated by astrocytes and infiltrating tumor-associated microglia and macrophages (TAMs)<sup>11,12</sup>. Recently, signaling mediated by hepatocyte growth factor (HGF) and the related 98 receptor MET (c-MET, HGFR) was identified as the trigger of reactive microglia<sup>13</sup>. HGF is 99 100 thereby secreted by microglia in the context of trauma but also under normal conditions and 101 seems to play a special role in the growth and self-renewal of neural stem cells in the 102 subventricular zone (SVZ) of rat brains<sup>14,15</sup>. Therefore, metastatic melanoma cells expressing 103 MET might scavenge HGF from the brain for activation of processes downstream of MET 104 mediating survival and proliferation.

Here, we used transcriptome and methylome profiling to unravel the epigenetic and transcriptomic landscapes of MBM that featured infiltration of TAMs with emphasis on the

potential role of microglia in the activation of the HGF/MET receptor signaling pathway. The
MET receptor inhibitors PHA-665752 and tivantinib (ARQ197) effectively blocked the growth
of brain metastases derived cells (BMCs). Hence, targeting MET receptor signaling might
serve as a potent therapeutic target for brain metastases lacking druggable BRAF<sup>V600</sup>
mutations.

#### 112 **Results**

#### 113 A microglia-specific gene cluster discriminates MBM

Microglia are a unique population of antigen-presenting cells in the central nervous system (CNS) that are capable of clearing the brain of microbes, dead cells and protein aggregates<sup>16</sup>. Besides, microglia play a crucial role during injury repair and display an exceptional role in immune surveillance and tumor clearance<sup>17,18</sup>. Although the role of tumorassociated microglia and macrophages (TAMs) in primary brain tumors such as glioblastoma<sup>19-22</sup> has been intensively studied, their role in the progression of brain metastases remains poorly understood.

We performed immunohistochemistry (IHC) of our MBM cohort (Supplementary table 1 121 and<sup>23</sup>) to determine the levels of activated, Iba1<sup>high</sup> TAMs. Although Iba1/AIF1 serves as a 122 123 well-established marker, reactive microglia cannot be distinguished from brain infiltrated macrophages<sup>24</sup>. Initial studies of MBM revealed that Iba1/AIF1 levels classified tumors into 124 125 highly and lowly TAM infiltrated (Figure 1a, Supplementary figure 1a). Moreover, we observed overlapping patterns of infiltration of Iba1<sup>high</sup> TAMs and CD3<sup>+</sup> T cells (Figure 1b). As 126 CD3 only provided information about levels of T cell infiltration, we used the ESTIMATE 127 algorithm<sup>25</sup> to gain insight into the overall degree of immune cell infiltration of MBM. In line 128 with our previous observation, tumors with intensive TAM and T cell infiltration exhibited a 129 high immune score (Pts 3, 4, 10, 12) whereas MBM with low levels of Iba1<sup>high</sup>/ CD3<sup>+</sup> cell 130 131 infiltration (Pts 1, 2) or low expression of Iba1/AIF1 (Supplementary figures 1b, c) showed 132 low immune scores (Figure 1c). As expected, brain metastases derived cell lines (BMCs) 133 with absence of immune cells featured lowest scores (Supplementary figures 1b, c). The

134 brain has long been considered a sanctuary where tumor cells can grow undisturbed and 135 protected from attack by immune cells. Therefore, we next investigated expression levels of 136 Iba1/AIF1 in brain (MBM) and extracranial metastases (EM). We observed AIF1 expression 137 in both as well as a high correlation with immune score (Figure 1d), suggesting a relationship 138 between levels of infiltration of TAMs and immune cells not only in the brain. As high levels of immune cell/T cell infiltration are generally associated with good prognosis<sup>26</sup>, we determined 139 the probability of survival related to Iba1/AIF1 expression of patient's with (study 140 141 EGAS00001003672) and without (TCGA-SKCM) MBM. We observed beneficial effects of 142 high Iba1/AIF1 levels in the TCGA cohort (HR=0.46 (0.35 - 0.62), logrank p=1.3e-07) 143 (Figures 1e, f), however, Iba1/AIF1 level had no beneficial effects on the survival of MBM 144 patients. Since no data on TAM-infiltrated MBM are available, we performed comparative methylome and transcriptome profiling of Iba1<sup>high</sup> (n=5-10) and Iba1<sup>low</sup> (n=2-6) tumors and 145 146 identified a set of 417 differentially methylated genomic regions (DMRs) that corresponded to 294 MBM expressed genes (Figure 1g) a core set of markers (n=31) sufficient to split tumors 147 148 (Figure 1h; Supplementary tables 2, 3). Among them, we identified the integrin family 149 member and gut-homing receptor ITGB7 -which we described in our previous study as a distinguishing mark between BRAF and NRAS mutant MBM<sup>23</sup> - and APBB1IP (amyloid b 150 precursor protein-binding family b member 1 interacting protein). Both are associated with 151 better prognosis in patients with colorectal cancer<sup>27,28</sup> and clustered with known TAM-152 153 associated genes such as P2RY12 and AIF1 (Figure 1h). Remarkably, all clustered tumors 154 were associated with a high immune score. A correlation analysis of clustered genes 155 revealed a high degree of correlation among each other (Figure 1i) and association with hepatocyte growth factor (HGF) that was recently connected with microglia activation<sup>13</sup>. 156 157 However, only some of the identified markers within the gene cluster were specifically 158 expressed in microglia but not in brain infiltrating macrophages or other brain cells such as APBB1IP (Figure 1). The latter gene which has been identified as a conserved microglial 159 gene<sup>29</sup> and binding partner of amyloid precursor protein (APP), Tau, 14-3-3g, and glycogen 160 161 synthase kinase 3 b (GSK3 b) was associated with actin dynamics and retinoic acid

signaling<sup>30,31</sup>. Expression of APBB1IP was significantly (MBM: R=0.86, p<2.2e-16) correlated 162 163 with immune score (Figure 1k) and survival of melanoma patients (Supplementary figures 164 1d-e). Moreover, our survey identified a differentially methylated side (Supplementary table 165 4) within the promoter of PD-L2 (PDCD1LG2) that may predict progression-free survival in melanoma patients receiving anti-PD-1 immunotherapy<sup>32</sup>. PD-L2 expression was associated 166 with favorable survival (p=0.020) of patients with MBM (Supplementary figure 1f). We found 167 168 additional genes among our cluster that were expressed in TAMs and significantly 169 associated with immune score (Supplementary figures 1g-n).

170

#### 171 Expression of ITGB7 serves as indicator of immune cell infiltration

172 Recent studies have shown that ITGB7 plays a critical role in the recruitment of T cells to the 173 intestine and that downregulation of ITGB7 is important in protecting intestinal tumors from attack by activated T cells<sup>27,33</sup>. Hence, we sought to investigate *ITGB7* in more detail. Mining 174 of publicly available immune cell data (studies GSE146771<sup>34</sup>, DICE database<sup>35</sup>) revealed 175 176 expression of ITGB7 across different immune cell stages including naïve and memory 177 subsets of T cells, B cells and NK cells (Figure 2a and Supplementary figure 2a). We found 178 that *ITGB7* was rather expressed in MBM with infiltration of immune cells and particularly within immune cell dense areas (Supplementary figure 2b). Co-staining revealed 179 accumulation of CD3<sup>+</sup> T cells as well as of Iba1<sup>high</sup> TAMs (Figure 2b). Ranking of MBM 180 181 regarding levels of *ITGB7* expression showed co-occurrence in the expression of CD4, 182 CD274, Sushi Domain Containing 3 (SUSD3) and ITGB7 level (Figure 2c) and validated a possible, previously observed<sup>23</sup> correlation of *ITGB7* and SUSD3. Moreover *ITGB7*, SUSD3 183 184 and APBB1IP showed expression across different immune cell types except for monocytes 185 and NK cells (Supplementary figures 2c-f). Global (850k) methylome profiling uncovered four 186 epigenetic regulation sites of ITGB7 (Supplementary table 4) with two sites that were 187 associated with expression levels and immune score (Figures 2d, left and center panel, 188 Supplementary figure 3a), located in a proximal enhancer-like region (probe cg26689077) or 189 near by the promotor of ITGB7 (probe cg01033299). The latter site was also identified in the

medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297080; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

190 TCGA-SKCM cohort. The sites did not correlate with the BRAF mutation status of MBM 191 (Figures 2d, right panel) in contrast to additional two sides that were found within intergenic 192 regions including an CpG island located between exons 4 and 5 (probes cg11510999 and 193 cg18320160; Supplementary figures 3b-e).

Hence, methylome profiling of MBM identified two DMRs within the *ITGB7* gene that might
serve as indicators of the degree of immune cell infiltration.

196 A recent study demonstrated that MBM feature a lower T cell content than matched 197 extracranial metastases, however response rates to ICi of both were comparable<sup>36</sup>. 198 Assuming that ITGB7 expression might be crucial for T cell recruitment, we ascertained 199 ITGB7 levels in MBM (n=79) and EM (n=59; study EGAS00001003672). We observed that 200 ITGB7 was expressed in both metastatic subtypes and was significantly correlated (MBM: 201 R=0.51, p=1.8e-06; EM: R=0.69, p=1.1e-09) with the tumor's immune scores (Figure 2e). As 202 we suggest that *ITGB7* expression might indicate the degree of immune cell infiltration and 203 possibly serve as indicator of response to ICi, we next performed correlation analysis of 204 ITGB7 and known markers of T cells and B cells. We observed a high concordance with 205 immune cell-related but not tumor cell-related genes (NGFR, MITF, MLANA, SLC45A2) and 206 correlation with expression of PDCD1LG2 (PD-L2) and SUSD3, irrespective of the side of 207 metastasis (Figures 2f, g). In line with previous observations, ITGB7 was expressed in 208 primary and metastatic tumors (TCGA-SKCM) and like SUSD3 was associated with favored 209 survival (Figure 2i). In summary, our survey identified a set of markers that are potentially 210 associated with the level of TAM/immune cell infiltration, particularly ITGB7 might serve as a 211 marker for a favorable course of the disease.

212

A signature-based deconvolution revealed MET receptor signaling in microglia enriched MBM

215 Our previous survey identified a set of markers that potentially characterize a molecular subset of MBM, likely showing a favorable course and response to ICi therapy<sup>37,38</sup>. To further 216 217 characterize this set of tumors, we performed single-sample Gene set Enrichment-Analysis 218 (ssGSEA) using defined immune-related and gene signatures specifying signaling processes 219 such as MET receptor or STAT3 signaling among others that are reported to be involved in 220 immune-response mechanisms (Supplementary table 5). We observed that MBM featuring a 221 high immune score showed activation of MET and STAT3 signaling, increased tumor 222 inflammation, stress and senescence (SenMayo<sup>39</sup>) (Figure 3a). Moreover, deconvolution 223 revealed the presence of reactive microglia, astrocytes and immune cell subsets, among them stem cell-like CD8<sup>+</sup> T cells (TCF7)<sup>40</sup> in tumors, absent in BMCs. CD8<sup>+</sup> (TCF7) T cells 224 225 are necessary for long-term maintenance of T cell responses and predicted positive clinical 226 outcome<sup>41,42</sup>. Signatures clearly discriminated MBM and BMCs and reinforced the differences of Iba1<sup>high</sup> (Pts 3, 4) and Iba1<sup>low/neg</sup> (Pts 1, 2) tumors. We therefore suggest that the activation 227 228 of MET- or STAT3-mediated signaling processes or those related to stress/senescence or 229 inflammation strongly depend on the composition of the tumor microenvironment, likely 230 determining the response to the rapeutic interventions. Although infiltration of TAMs is not 231 evident in all MBM, microglia infiltration seems to be an early occurring process observed 232 ~21d after intracranial injection of BMCs into brains of immune compromised CrI:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup> (Figure 3b). Moreover, we observed activation of Stat3 signaling in tumor 233 234 adjacent cells (Figure 3b), suggesting that brain microenvironmental cells are activated after 235 a short time of tumor-stroma interaction and establish an inflammatory environment. We 236 performed ssGSEA and applied the above mentioned signatures and observed a 237 comparable pattern of enrichment in a more comprehensive and independent set of MBM (study EGAS00001003672<sup>43</sup>, n=79 MBM) (Supplementary figure 4a). 238

HGF or scatter factor (SF) is the only identified ligand of MET, plays a pivotal role during neural development, regulating growth and survival of neurons<sup>15,44</sup> and likely serves as inducer of reactive microglia by an autocrine loop in response to trauma or neurodegenerative disorders<sup>13</sup>. Therefore, MET expressing, brain colonizing melanoma cells

243 may benefit and take advantage of the HGF-controlled systems naturally occurring in the 244 brain. We observed HGF expression among tumors of different data sets comprising MBM, 245 EM and primary tumors (studies EGAS00001005976; TCGA-SKCM; EGAS00001003672) 246 with no significant difference of HGF levels in tumor subsets (Figures 3d, e). Investigation of immune cell and brain cell data (DICE database<sup>35</sup> and study GSE73721<sup>45</sup>) revealed high 247 expression of HGF in monocytes and astrocytes (Figures 3f, g), suggesting a potential role of 248 249 different stroma cell populations for activating HGF/MET signaling in brain-infiltrating tumor 250 cells. Assuming that the degree of microglia infiltration determines signaling processes in 251 MBM cells, we explored expression levels of MET signaling-associated genes in tumors with 252 high and low level of infiltrated TAMs and found levels of HGF, PIK3CG, PTK2B, STAT3 and 253 MAP4K1 significantly correlated with microglia score (Supplementary figure 4c-e) that was 254 defined as average expression level or β-value of microglia markers APBB1IP, SYK, HCK 255 and P2RY12 (Supplementary table 6).

256 HGF might be released by immune cells as well as homeostatic and reactive microglia or 257 astrocytes. We surveyed the Seattle Alzheimer's Disease Brain Atlas which is implemented 258 in the Allen brain atlas database (https://portal.brain-map.org/) and observed that dementia 259 fostered expansion of microglia with increased expression of HGF (Figure 3h, center and 260 right panels). Reactive microglia and immune cell released HGF might hence be responsible 261 for activation of growth factor/survival signaling in adjacent tumor cells. In line with previous 262 studies, we observed a significant correlation of HGF expression with immune score in brain 263 (BM, R=0.49, p=5.3e-06) and extracranial metastases (EM, R=0.41, p=1.5e-03), (Figure 3i).

264

#### 265 Expression and activation of MET receptor classifies a molecular subset of MBM

Understanding the molecular mechanisms that establish cellular dependencies and thus control the development and maintenance of brain metastases is critical for their therapeutic manipulation. Recently, we identified that the expression of Ecad and NGFR sufficiently discriminated molecular subsets of MBM<sup>23</sup>. These subsets likely distinctly interact with microenvironmental cells and respond to therapeutics (Figure 4a). To identify potential

271 druggable targets, we surveyed the pan-MBM, NGFR and Ecad-specific gene sets for cell 272 surface receptors that may serve as crucial key factors that control tumor cell maintenance 273 and expansion and identified 24 receptors that distinguished Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors 274 (Figure 4b). Particularly ADIPOR1 (adiponectin receptor 1, p=1.9e-02), SIRPA (signal 275 regulatory protein alpha, p=1.1e-05) and PLXNC1 (plexin C1) showed significantly increased 276 expression in Ecad<sup>+</sup> MBM and EM but comparable levels among MBM and EM (Figure 4c). 277 In addition, Ecad<sup>+</sup> MBM featured increased levels of MET receptor in (p=1.4e-04). MET was 278 significantly (p=2.7e-05) higher expressed in MBM than EM (Figure 4d, left and center 279 panels). The MET tyrosine kinase receptor pathway serves as a potent survival and maintenance factor for MBM and might be a promising therapeutic target<sup>46</sup>. MET expression 280 281 was associated with increased cell cycle progression and proliferation (Figure 4d, right panel) 282 and defined yet another subset of MBM (Figure 4e). Next we assessed whether expressed 283 MET indeed participated in active signaling processes. Phosphorylation of MET at tyrosine residues 1234/1235 (pMET<sup>Y1234/1235</sup>) is critical for kinase activation and initiation of 284 downstream processes and was evident in nearly all MET<sup>high</sup> MBM investigated, independent 285 286 of the BRAF mutation status (Figures 4f, g). MET receptor alterations are evident in 9 % of all 287 SKCM melanoma cases, including amplification as observed in 1.13 - 17.2% or 11% of melanoma (TCGA-SKCM, study by Ramani et al.47). However, targeted DNA sequencing 288 289 (TargetSeq) and fluorescence in-situ hybridization (FISH) revealed absence of MET 290 activating mutations and a tendential MET amplification in only one case (Pat 5, 291 Supplementary figure 5a, b). However, all but one tumor (Pat 14) showed high polysomy. As 292 we assume that environmental cells foster activation of MET receptor signaling in a subset of tumor cells, we performed co-IHC for pMET<sup>Y1234/1235</sup> and Iba1. We observed pMET<sup>Y1234/1235</sup> 293 positive tumor cells in close proximity to Iba1<sup>high</sup> TAMs (Figure 4h), though MET receptor was 294 not activated in Iba1<sup>high</sup> microglia that resided in adjacent normal tissue (Supplementary 295 296 figure 5c, upper panel). However, MET receptor activation was also evident in scattered tumor cells in the absence of adjacent Iba1<sup>high</sup> TAMs (Supplementary figure 5c, lower panel) 297 298 suggesting paracrine mechanisms or additional sources of HGF such as immune cells or

299 astrocytes. Considering that HGF levels, like those of other growth factors provided by 300 stromal cells, might depend on spatial factors, we examined the Allan Brain Atlas database 301 and found that HGF is comparably expressed in different brain sections (frontal lobe (FL), 302 parietal lobe (PL), temporal lobe (TL), occipital lobe (OL)) but is lowly abundant in the 303 brainstem (pons) (supplemental Figure 5d). The spatially dependent expression of growth 304 factors in the brain may therefore determine the dependencies of the tumor cells.

305

# Interferon signaling determines response of MBM to immune checkpoint inhibitor therapy

Interferon-gamma signaling has been identified as an important mechanism for upregulation of PD-L1 on melanoma cells and escape from immune recognition. On the other hand, recent studies uncovered that high interferon-gamma-related gene expression signature scores (IFN- $\gamma$  score) were associated with low risk of melanoma relapse from neoadjuvant ipilimumab plus nivolumab therapy<sup>48,49</sup>.

313 In our recent study, we observed significant enrichment of interferon and inflammatory response ("Hallmark", MsigDB<sup>50</sup>) signatures in MBM with high level of tumor infiltrating 314 lymphocytes (TIL<sup>high</sup>)<sup>23</sup> that have been attributed with favored survival in a pre-clinical 315 316 melanoma model<sup>49</sup>. We found overlapping expression of ITGB7, SUSD3 and HGF and 317 Hallmark interferon-response genes, separating MBM of our cohort and MBM of study 318 EGAS00001003672 (Figure 4i, Supplementary figure 6a). Expression of *ITGB7* significantly 319 correlated with levels of interferon regulatory factor 1 (IRF1) and IRF8 in MBM (BM) and 320 extracranial metastases (EM) of study EGAS00001003672 (Supplementary figure 6b-d). 321 Moreover, we observed high correlation of levels of HGF, IRF1 and IRF8 in MBM 322 (Supplementary figure 6e). As microglia serve as a source of soluble receptor ligands such 323 as Hgf, we next surveyed data of interferon-gamma treated (1 U/mL IFNy, 24h) murine 324 microglia cells (BV2, GSE132739). Indeed, we found significant upregulation of ltgb7 (p = 325 2.9e-03) and Hgf (p=4.4e-02) but downregulation of Susd3 (p=4.0e-02) in BV2 cells 326 (Supplementary figure 6f). For control, we investigated levels of known interferon-responsive

327 genes that were significantly increased 24h after interferon treatment, Mx1 (p=1.2e-02), PD-328 L1/Cd274 (p=3.6e-02), Irf1 (p=3.1e-02) Cxc/9 (p=4.0e-03) and Aif1 (p=3.9e-04) 329 (Supplementary figure 6g). In order to classify MBM of our study into anti-PD-L1 responsible 330 and non-responsible and for linking ITGB7, SUSD3 and HGF with therapy response, we 331 performed ssGSEA and applied interferon responsive and additional immune response gene 332 signatures (of study GSE186344<sup>51</sup>). Our survey validated that *ITGB7*, *SUSD3* and *HGF* were 333 highly expressed in MBM that featured enrichment of interferon responsive genes/signatures 334 (Pts. 3-6, 12; Supplementary figure 6h).

335

Hence, we suggest that *ITGB7*, *SUSD3* and *HGF* like *PD-L1* are among the interferonregulated genes triggered by immune cell-released interferon-gamma and may be involved in immune response mechanisms of MBM.

339

#### 340 The targeting of MET receptor serves as a promising strategy to control MBM growth

341 Although a subset of MBM exhibit immune cell subset enrichment and interferon response 342 signatures and respond to ICi therapy, MET-expressing brain metastatic melanoma cells 343 may benefit from HGF released by stromal cells to drive progression. Hence, activation of 344 MET signaling may depend on the degree of tumor-stroma interaction, possibly 345 counteracting the beneficial impact of immune checkpoint inhibition (ICi). Resistance-346 mediating processes include the phosphorylation of ribosomal protein S6 (pS6), which is downstream of MET and mTOR signaling<sup>52</sup> and was observed in progressive BRAFi-resistant 347 melanomas<sup>53,54</sup>. 348

We assessed pS6 phosphorylation of serine residues 235/236 and found co-occurrence of activated MET receptor and of pS6<sup>235/236</sup> in MITF positive tumors (Figure 5a and Supplementary figures 7a, b). Moreover, pS6 phosphorylation was evident in a BRAF<sup>wt</sup> (T2002) and mutated (V600E, BMC53) cell lines probably suggesting a general activation of pS6 signaling irrespective of the presence of mutated BRAF (Figure 5b). As MET signaling might serve as mediator of a resistance-mediating program, we assessed the efficacies of

355 the ATP-competitive inhibitor PHA-665752 and the non-ATP-competitive, clinical phase I/II 356 MET receptor inhibitor (METi) tivantinib (ARQ197) in BMCs that showed variable levels of 357 MET expression (Figure 5c and Supplementary figure 7c). ARQ197 failed to improve the outcome and overall survival of patients with hepatocellular carcinoma<sup>55</sup> but may potentially 358 359 be effective in melanoma patients. The initial testing revealed a general response of BMCs 360 (BMC1-M1, BMC53), T2002 cells and conventional cell lines (A375, A2058, MeWo) to both 361 inhibitors irrespective of the BRAF mutation status (Figures 5d, e). As we observed a 362 mutually exclusive rather than co-expression of MET receptor and NGFR (nerve growth 363 factor receptor), we tested whether the manipulation of NGFR levels might affect the 364 response to PHA-665752 (PHA). We observed that overexpression of NGFR in A375 cells (A375<sup>NGFR</sup>) sensitized to METi compared to RFP expressing control (A375<sup>RFP</sup>) or MeWo cells 365 366 (Figure 5f). Next, we asked whether METi targeting may serve as alternative therapeutic strategy for BRAFi resistant (BMC4) or cells with non-BRAF<sup>V600</sup> mutations (BMC2) showing 367 368 only moderate or no response to dabrafenib (Figure 5g) as indicated by IC<sub>50</sub> values (BMC4, 369  $IC_{50} = 226.4$  nM and BMC2,  $IC_{50} = 3029.5$  nM). The broad range (1nM - 10µM) testing of 370 tivantinib in BMCs, T2002 and conventional melanoma cells and PHA in BMCs revealed that 371 all cell lines responded to both METi, irrespective of the mutation status. However, we 372 observed that the non-(brain) metastatic cell lines A375, A2058, and T2002 were more 373 sensitive to treatment with tivantinib than BMCs (Figures h-j, Supplementary figure 7d). The 374 median IC<sub>50</sub> value of BMCs was ~600 nM (range: 406.5 – 800.1). Cell lines lacking BRAF 375 and NRAS mutations (MeWo, T2002) showed highest responses to tivantinib (Figure 5k).

376

In summary, brain metastatic as conventional melanoma cell lines responded to METi, suggesting that targeting of MET signaling might be a promising tool for the treatment of non-BRAF<sup>V600</sup> and BRAF<sup>V600</sup> mutated MBM that acquired resistance to BRAFi or for combinatorial of METi and ICi in NRAS mutated tumors.

- 381
- 382

## 383 **Discussion**

The spatiotemporal development of primary and secondary brain tumors is strongly determined by the crosstalk of tumor and brain micronenvironmental cells, particularly macrophages, astrocytes and microglia<sup>56</sup> and the consequential activation of inflammatory processes<sup>57</sup>. Although the neuro-inflammatory processes that are activated alongside development and progression of primary brain tumors such as glioblastoma have been intensively studied, the mechanisms that accompany emergence of brain metastases on the other side are not well investigated.

391 Here, we used combined transcriptome and methylome profiling to unravel the molecular 392 features of MBM of different progression stages showing high and low level of tumor-393 associated macrophages/microglia (TAMs) infiltration, irrespective of the phenotype (Ecad, NGFR). Generally, TAMs foster development and progression of primary brain tumors<sup>58,59</sup>, 394 395 however their functional role in MBM may be different. We observed that MBM containing a 396 high proportion of TAMs were associated with a high immune score and infiltration of CD3<sup>+</sup> T cells. The profiling of Iba1/AIF1<sup>high</sup> tumors revealed a cluster of genes, among them *ITGB7*, 397 398 APBB1IP as SUSD3 and PD-L2, that were widely expressed among immune cell subtypes and previously associated with increased immune T cell infiltration<sup>23,27,28,33</sup> and favored 399 400 outcome. Previous mouse studies demonstrated a pivotal role of ITGB7 for intestinal T cell 401 recruitment and correlated low levels of ltgb7 with colorectal cancer progression and maintenance of intestinal stem cells via Ecad-mediated interaction<sup>27,33</sup>. However, we 402 403 observed strong protein expression of ITGB7 in immune cells adjacent to tumor cells of 404 Ecad<sup>+</sup> and NGFR<sup>+</sup> tumors, suggesting a broader function of ITGB7 in different subtypes of 405 metastases and cancers. Enhanced expression of ITGB7 might be a prerequisite for immune 406 cell invasion. Therefore, epigenetic marks that correlate with the expression of ITGB7 and 407 other genes mentioned above may be of prognostic importance, and the expression of these 408 markers could determine the pathways of intracranial progression.

409 As previously described for the Ecad<sup>+</sup> and NGFR<sup>+</sup> subtypes of MBM, whether tumors are 410 enriched or depleted in TAMs and immune cell subsets is critical and may determine 411 response to therapeutic intervention. The subsequent ssGSEA-based characterization of 412 MBM of studies performed by us and others revealed molecular programs fostering or 413 accompanying the TAM<sup>+</sup>/TIL<sup>+</sup> tumor subtype. TAM<sup>+</sup>/TIL<sup>+</sup> tumors featured activation of MET 414 and STAT3 signaling, increased stress response, tumor inflammation, senescence and 415 activation of microglia and astrocytes but also activated interferon signaling. STAT3 416 activation in tumor-adjacent astrocytes in response to brain damage or tumor cells is wellinvestigated process<sup>60,61</sup> and was rapidly induced in response to brain infiltrating BMCs. 417 418 Hence, enrichment of STAT3 signature genes was likely attributed to tumor-adjacent astrocytes and infiltrated immune cells<sup>62</sup>. 419

420

421 The HGF/MET receptor signaling plays a pivotal role during brain development and neuroregeneration, homeostasis of microglia and neurons<sup>14,44</sup> but is also involved in microglia 422 activation in response to trauma<sup>13,44,63</sup>. Brain infiltrating melanoma cells hence may engage 423 424 the HGF/MET signaling of brain cells and utilize for regulation of survival and proliferation. 425 We observed expression of MET receptor in the subset of E-cadherin (Ecad) expressing tumors<sup>23</sup>, suggesting that Ecad<sup>+</sup> but not NGFR<sup>+</sup> cells may depend on HGF/MET signaling. As 426 427 we observed that HGF is expressed by immune cell subsets and homeostatic or reactive 428 astrocytes and microglia, we investigated the level of activated/phosphorylated MET receptor in TAM-adjacent tumor cells. We found that tumor cells but not Iba1<sup>high</sup> TAMs that resided in 429 430 tumor cell-free adjacent stroma showed activation of MET, however MET was also activated 431 in the absence of adjacent microglia in some tumor cells, suggesting a paracrine effect of HGF. In line with our previous study<sup>23</sup>, we observed enrichment of interferon-response 432 signatures in the subset of TIL<sup>high</sup>/immune score (IS)<sup>high</sup> tumors. We observed enrichment of 433 interferon-response genes in MBM with high levels of ITGB7 expression and observed 434 435 significant response of Itgb7 and Hgf among known interferon-inducible genes such as Cd274<sup>64</sup> and Mx1<sup>65</sup> in interferon-gamma treated BV2 murine microglia cells (unpublished 436

study GSE132739). Hence, T cell-provided interferon-gamma might not only induce
expression of Cd274/PD-L1 but may also activate expression of HGF and ITGB7. Therefore,
autocrine MET receptor signaling might be triggered in response to immune cell released
interferon-gamma and/or paracrine activation of MET signaling may occur via (INFGactivated) reactive glia-released HGF.

Our study bridges the gap between the immune cell phenotype of MBM and the activation of potentially therapeutic counteracting signaling pathways. The infiltration of TAMs and immune cells thus represents a double-sided sword and on the one hand is associated with an effective response to immune checkpoint inhibitors, but on the other hand can support the growth of MET expressing tumor cells via secreted factors such as HGF.

447 Therefore, we finally assessed the potential role of small molecule inhibitors of MET receptor (METi) for targeting of MBM that lack druggable BRAF<sup>V600</sup> mutations or developed refractory 448 disease. To this end, we took advantage of well-characterized BMCs serving as in vitro 449 450 model systems. We observed that the ATP-competitive inhibitor PHA-665752 and the non-451 ATP-competitive, clinical phase II inhibitor ARQ197 (tivantinib) elicited response in BMCs 452 and conventional melanoma cell lines irrespective of the BRAF/NRAS mutation status. 453 However, although being effective at doses of 100 – 200 nM in MeWo and A375 cells, 454 ARQ197 showed a median IC<sub>50</sub> value of ~1  $\mu$ M in BMCs, suggesting a general difference 455 among brain metastatic and long-term maintained conventional cell lines established from 456 either non metastatic (A375) or locally metastatic (MeWo) cells.

In summary, we have shown that MET receptor signaling is active in a subset of MBM, conferring a survival/growth benefit independent of BRAF/NRAS mutation status. MET activation may occur in response to HGF released by TAM/immune cells and could counteract therapeutic interventions. Furthermore, we suggest interferon-induced expression of HGF in tumor cells triggered by interferon-gamma provided by stromal cells mediates autocrine activation of MET-signaling tumor cells (Figure 6). In addition, we demonstrated that methylome profiling of MBM has high potential to identify gene regulatory sites that may

predict favorable progression of intracranial disease. In the present study, we identified epigenetic regulatory sites in a group of genes comprising *ITGB7*, *APBB1IP*, *SUSD3* and PD-L2 (*PDCD1LG2*).

467

#### 468 Limitations of the study

The present study is not without limitations. Although we suggested that HGF/MET signaling is activated in tumor cells in close proximity to infiltrated microglia, we have not provided evidence that growth of established brain tumors and phosphorylation of MET decreases in response to METi. Moreover, whether METi are capable of passing the blood-brain barrier and not affect normal homeostatic processes e.g. those crucial for neuron survival needs to be investigated.

475

### 476 Methods

#### 477 Patient cohorts

All procedures performed in this study were in accordance with the ethical standards of the respective institutional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients gave written informed consent for the collection and scientific use of tumor material which was collected at the Biobank of the Charité – Comprehensive Cancer Center (CCCC). The study was approved by the Ethics Committee of the Charité (EA1/152/10; EA1/107/17; EA4/028/18 and EA1/107/17 and EA1/075/19) and Universitätsmedizin Greifswald (BB 001/23).

485

#### 486 Cultivation of MBM-derived and conventional melanoma cell lines

487 All cell lines were cultured as previously reported<sup>23</sup>. Briefly, all brain metastases-derived cell 488 lines (BMCs) and conventional melanoma cell lines were kept at  $37^{\circ}$ C/ 5% CO<sub>2</sub> and 95% 489 humidity in cell culture medium (DMEM, 4.5 g/L glucose, stabilized glutamine/GlutaMax,

pyruvate, Gibco/ThermoFisher) supplemented with 10% fetal bovine (FBS, Gibco) serum and
1% penicillin/streptomycin (P/S) (Gibco/ThermoFisher) and routinely passaged. BMCs were
established from intraoperative tumors as previously reported<sup>23</sup>.

493

#### 494 Live cell imaging-based drug sensitivity assays

495 Drug treatments were performed 24 h after seeding of 2,500-5,000 cells/96-well in 100 µl 496 medium. The response of BMCs and conventional melanoma cell lines to dabrafenib. PHA-497 665752 or ARQ197 (all purchased from Selleckchem) in a range of 1nM-10µM of eight 498 technical replicates was determined by live cell imaging. Images were taken every three 499 hours using a 10x objective and the general label-free mode, two pictures of eight technical 500 replicates per condition were taken. Drug response was assessed by changes in the cellular 501 density over time. The cell density was determined by a confluence mask tool as part of the 502 IncucyteS3 software. IC50 values were calculated by curve-fitting (https://search.r-503 project.org/CRAN/refmans/REAT/html/curvefit.html) based on confluence measurements at 504 day 3.

#### 505 In vivo experiments

506 All animal experiments were performed in accordance with the German Animal Protection 507 Law under the permission number G0130/20 obtained via the Berlin Ministry of Health and 508 Social Affairs (LaGeSo). ARRIVE 2.0 Guidelines were strictly followed and performed as previously reported<sup>23</sup>. Briefly, 2.5x10<sup>4</sup> BMC1-M4 and BMC2 cells were stereotactically 509 inoculated into brains of female Crl:CD1-Foxn1<sup>nu</sup> nude mice (8-9 weeks of age, 24-26g, 510 511 Charles River Laboratories) were with using a 1µl Hamilton syringe and a stereotactic frame as described previously<sup>66</sup>. Tumor growth was tracked by MRI and animals were sacrificed by 512 513 perfusion with 4% PFA in deep anesthesia after tumors reached a volume of 20 mm<sup>3</sup>. 514 Following, whole brains were removed, dehydrated, paraffin embedded and sections of 2 µm 515 were used for downstream analyses.

516

517

#### 518 **RNA isolation and sequencing**

519 Isolation of total RNA from snap frozen tumors and RNA sequencing was performed as 520 previously reported<sup>23</sup>. Briefly, 100 ng of total RNA was used for library preparation with 521 TruSeg Stranded total RNA Sample Preparation-Kit and Ribo-Zero Gold Kit (Illumina). 522 Paired-end (2x100 bp) sequencing of RNA libraries with integrity numbers (RIN)  $\geq$ 7 was 523 performed on NovaSeq6000 platform at Cegat GmbH, Tuebingen (Germany). Following demultiplexing of sequenced reads and adapter trimming<sup>67</sup>, FASTQ files were obtained. Raw 524 525 of were normalized the counts protein-coding genes using DESeq2 (https://bioconductor.org/packages/ release/bioc/html/DESeq2.html) package<sup>68</sup>. Differential 526 527 expression of genes between groups was determined after fitting models of negative 528 binomial distributions to the raw counts. Raw p-values were FDR (false discovery rate)-529 adjusted for multiple testing and a value below 0.05 for the adjusted p-values were used to 530 determine significant differentially expressed genes.

531

#### 532 Gene-set enrichment GSEA/Single-sample GSEA/Scores

533 GSEA was performed using the most current BROAD javaGSEA standalone version 534 (http://www.broadinstitute.org/gsea/downloads.jsp) and gene signatures of the molecular signature database MsigDB<sup>50,69</sup>, v7.4. In addition, we performed GSVA/ssGSEA using R 535 536 packages GSVA<sup>70</sup>, GSRI, GSVAdata and org.Hs.eg.db and a customized collection of gene 537 signatures including the signatures provided by Biermann et al.<sup>71</sup> and own signatures as defined by selected Ecad<sup>23</sup>, NGFR<sup>23</sup>, microglia or TME core genes (this study). All gene 538 539 signatures are shown in Supplementary table 5. Microglia scores were defined as the mean 540 β-value of probes cg24400465 (APBB1IP), cg05128364 (SYK), cg21704050 (P2RY12) and 541 cg03498995 (HCK) or expression levels (log2 FPKM) of these markers. The proliferation 542 index in Figure 4d was defined as mean expression level of the cell cycle regulators PCNA, 543 MKI67, CCNB1 and CCNB2.

544

545

#### 546 Fluorescence in situ hybridization (FISH)

547 FISH analysis was performed on 4 µm sections of FFPE blocks. Slides were deparaffinized, 548 dehydrated and incubated in pre-treatment solution (Dako, Denmark) for 10 min at 95-99°C. 549 Samples were treated with pepsin solution for 6 min at 37°C. For hybridization, a Vysis MET 550 SpectrumRed/ Vysis CEP 7 (D7Z1) SpectrumGreen Probe (Abbott, Chicago, USA) was 551 used. Incubation took place overnight at 37°C, followed by counterstaining with 4,6-552 diamidino-2-phenylindole (DAPI). For each case, signals were counted in 50 non-overlapping 553 tumor cells using a fluorescence microscope (BX63 Automated Fluorescence Microscope, 554 Olympus Corporation, Tokyo, Japan). Computer-based documentation and image analysis was performed with the SoloWeb imaging system (BioView Ltd, Israel). MET high-level 555 amplification (MET FISH+) was defined as (a) MET/CEN7 ratio ≥2.0, (b) average MET copy 556 557 number/cell  $\geq$  6 or (c)  $\geq$ 10% of tumor cells with  $\geq$ 15 MET copies/cell as described in 558 Schildhaus et al<sup>72</sup>.

559

#### 560 Quantitative real-time RT-PCR

RNA isolation from frozen cell pellets was performed with the RNeasy Mini Kit (Qiagen, Germany) and, following the manufacturers protocol as previously reported<sup>23</sup>.qRT-PCR was carried out on a Step one plus PCR cycler (Applied Biosystems, Germany) for 30–40 cycles. Primers were designed for 55–60°C annealing temperatures. Relative expression levels were calculated with the ΔΔCT method<sup>73</sup>, normalized to β-actin. Primer sequences are shown in Supplementary table 7.

567

#### 568 Immunohistochemistry (IHC)/Immunofluorescence (IF)

Automated immunohistochemical staining was performed on formalin-fixed, paraffinembedded (FFPE) tissue sections using the BenchMark Ultra (Ventana) autostainer. The
following primary antibodies were used: CD3 (anti-CD3ε, Agilent, catalog number:
#A045201-2, rabbit, dilution: 1:100), pMET (phospho-MET, Tyr1234/1235, Cell signaling,

573 catalog number: #3077, rabbit, dilution: 1:100), pS6 (phospho-S6 ribosomal protein 574 Ser235/236, Cell signaling, catalog number: #2211, rabbit, dilution: 1:100), IBA1 (IBA1/AIF-1, 575 ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number: #17198, rabbit, 576 dilution: 1:100), ITGB7 (Integrin beta 7, Thermo Fisher, catalog number: #BS-1051R, rabbit, 577 dilution: 1:100) and pSTAT3 (phospho-STAT3, Tyr705, Cell signaling, catalog number: 578 #9145, rabbit, dilution: 1:100) and MITF (clones C5 + D5, Zytomed, catalog number: 579 Z2161MP, mouse, dilution: 1:100). Primary antibodies were applied and developed using the 580 iVIEW DAB Detection Kit (Ventana Medical Systems) or the ultraView Universal Alkaline 581 Phosphatase Red Detection Kit (Ventana Medical Systems). All slides were counterstained 582 with hematoxylin for 8 minutes. IF of mouse brain sections was performed with IBA1 583 (IBA1/AIF-1, ionized calcium-binding adaptor molecule 1, Cell signaling, catalog number: 584 #17198, rabbit, dilution: 1:100), KBA.62, NovusBiologicals, catalog number: NBP2-45285, 585 mAb mouse, 1:100; GFAP-AlexaFluor594, BioLegend, catalog number: 644708, mAb 586 mouse.

587

#### 588 **Data availability**

589 Whole transcriptome and methylome data were deposited in the European Genome-590 Phenome Archive (EGA), under accession numbers EGAS00001005975, 591 EGAS00001005976 (https://ega-archive.org/studies/). The data are available under 592 controlled access. Supplementary tables of our recent study have been deposited at Zenodo (https://doi.org/10.5281/zenodo.10006881). Supplementary tables of our previous study 593 594 containing a full list of patient's characteristics (Supplementary table 1) have been deposited 595 at Zenodo (https://zenodo.org/record/7013097 and https://doi.org/10.5281/zenodo.7249214).

596

## 597 Author contributions

598	TR performed data analyses, prepared figures and wrote the manuscript; ES collected
599	tumors, established BMCs and performed experiments; KP performed histological analyses;
600	MEW, SN and HWSS performed craniotomy and provided MBM; AV performed experiments/
601	drug response assays; HR provided expertise on microglia markers; AL performed MET-
602	FISH analyses; SKR provided funding; KJ performed bioinformatics data analysis and
603	expertise on data analysis; JR wrote the manuscript, provided resources and funding. All
604	authors have read and agreed to the published version of the manuscript.

605

## 606 **Competing interests**

607 The authors declare no conflicting interests.

608

## 609 Funding

JR is an alumnus of the BIH-Charité Clinical Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. We thank the German Cancer Consortium (DKTK), Partner site Berlin for technical support. AV received funding by the ÖAW (DOC Fellowship: DOC/26523).

614

## 615 Acknowledgments

616 We gratefully thank Cathrin Müller for excellent technical assistance.

- 618
- 619
- 620
- 621
- 622

## 623 **References**

- 6241Redmer, T. Deciphering mechanisms of brain metastasis in melanoma the gist of the625matter. *Mol Cancer* 17, 106, doi:10.1186/s12943-018-0854-5 (2018).
- Srinivasan, E. S., Deshpande, K., Neman, J., Winkler, F. & Khasraw, M. The microenvironment
  of brain metastases from solid tumors. *Neurooncol Adv* 3, v121-v132,
  doi:10.1093/noajnl/vdab121 (2021).
- Holt, M. G. Astrocyte heterogeneity and interactions with local neural circuits. *Essays Biochem* 67, 93-106, doi:10.1042/ebc20220136 (2023).
- 6314Hilscher, M. M. et al. Spatial and temporal heterogeneity in the lineage progression of fine632oligodendrocyte subtypes. BMC Biology 20, 122, doi:10.1186/s12915-022-01325-z (2022).
- 6335Li, Y. et al. Decoding the temporal and regional specification of microglia in the developing634human brain. Cell stem cell 29, 620-634 e626, doi:10.1016/j.stem.2022.02.004 (2022).
- 635 6 Tan, Y.-L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the brain.
  636 Molecular Psychiatry 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).
- 6377Liddelow, S. A. & Barres, B. A. Reactive Astrocytes: Production, Function, and Therapeutic638Potential. *Immunity* 46, 957-967, doi:10.1016/j.immuni.2017.06.006 (2017).
- 6398Bennett, M. L. & Viaene, A. N. What are activated and reactive glia and what is their role in640neurodegeneration? *Neurobiol Dis* 148, 105172, doi:10.1016/j.nbd.2020.105172 (2021).
- 541 9 Tan, Y. L., Yuan, Y. & Tian, L. Microglial regional heterogeneity and its role in the brain. *Mol*542 *Psychiatry* 25, 351-367, doi:10.1038/s41380-019-0609-8 (2020).
- 64310Mathys, H. et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-644Cell Resolution. Cell Rep 21, 366-380, doi:10.1016/j.celrep.2017.09.039 (2017).
- 64511Schwartz, H. et al. Incipient Melanoma Brain Metastases Instigate Astrogliosis and646Neuroinflammation. Cancer Res 76, 4359-4371, doi:10.1158/0008-5472.CAN-16-0485 (2016).
- 647 12 Colombo, E. & Farina, C. Astrocytes: Key Regulators of Neuroinflammation. *Trends Immunol*648 37, 608-620, doi:10.1016/j.it.2016.06.006 (2016).
- 64913Rehman, R. et al. Met/HGFR triggers detrimental reactive microglia in TBI. Cell Rep 41,650111867, doi:10.1016/j.celrep.2022.111867 (2022).
- 65114Yamagata, T. et al. Hepatocyte growth factor specifically expressed in microglia activated Ras652in the neurons, similar to the action of neurotrophic factors. Biochemical and biophysical653research communications 210, 231-237, doi:10.1006/bbrc.1995.1651 (1995).
- 65415Nicoleau, C. et al. Endogenous Hepatocyte Growth Factor Is a Niche Signal for Subventricular655Zone Neural Stem Cell Amplification and Self-Renewal. Stem Cells 27, 408-419,656doi:10.1634/stemcells.2008-0226 (2009).
- Schetters, S. T. T., Gomez-Nicola, D., Garcia-Vallejo, J. J. & Van Kooyk, Y. Neuroinflammation:
  Microglia and T Cells Get Ready to Tango. *Front Immunol* 8, 1905,
  doi:10.3389/fimmu.2017.01905 (2017).
- Colonna, M. & Butovsky, O. Microglia Function in the Central Nervous System During Health
  and Neurodegeneration. *Annu Rev Immunol* 35, 441-468, doi:10.1146/annurev-immunol051116-052358 (2017).
- 66318Caffarel, M. M. & Braza, M. S. Microglia and metastases to the central nervous system:664victim, ravager, or something else? J Exp Clin Cancer Res 41, 327, doi:10.1186/s13046-022-66502535-7 (2022).
- 66619Wang, G. et al. Tumor-associated microglia and macrophages in glioblastoma: From basic667insights to therapeutic opportunities. Front Immunol 13, 964898,668doi:10.3389/fimmu.2022.964898 (2022).
- 669 20 Blitz, S. E. *et al.* Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic 670 Virotherapy: A Double-Edged Sword. *Int J Mol Sci* **23**, doi:10.3390/ijms23031808 (2022).
- 67121Urbantat, R. M. et al. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in672Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance

673		Overcoming Strategy by Combination Therapy. Int J Mol Sci 22, doi:10.3390/ijms222011180
674 675	22	(2021). Andersen, R. S., Anand, A., Harwood, D. S. L. & Kristensen, B. W. Tumor-Associated Microglia
676	22	and Macrophages in the Glioblastoma Microenvironment and Their Implications for Therapy.
677		Cancers (Basel) 13, doi:10.3390/cancers13174255 (2021).
678	23	Radke, J. et al. Decoding molecular programs in melanoma brain metastases. Nature
679	25	Communications 13, 7304, doi:10.1038/s41467-022-34899-x (2022).
680	24	Köhler, C. Allograft inflammatory factor-1/lonized calcium-binding adapter molecule 1 is
681	24	specifically expressed by most subpopulations of macrophages and spermatids in testis. <i>Cell</i>
682		and Tissue Research <b>330</b> , 291-302, doi:10.1007/s00441-007-0474-7 (2007).
683	25	Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from
684	25	expression data. Nat Commun 4, 2612, doi:10.1038/ncomms3612 (2013).
685	26	Ros-Martinez, S., Navas-Carrillo, D., Alonso-Romero, J. L. & Orenes-Pinero, E. Immunoscore: a
686	20	novel prognostic tool. Association with clinical outcome, response to treatment and survival
687		in several malignancies. Crit Rev Clin Lab Sci 57, 432-443,
688		doi:10.1080/10408363.2020.1729692 (2020).
689	27	Zhang, Y. <i>et al.</i> Integrin beta7 Inhibits Colorectal Cancer Pathogenesis via Maintaining
690	27	Antitumor Immunity. <i>Cancer Immunol Res</i> <b>9</b> , 967-980, doi:10.1158/2326-6066.CIR-20-0879
691		(2021).
692	28	Ge, Q. et al. Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis. J
693	20	<i>Cancer</i> <b>12</b> , 595-610, doi:10.7150/jca.50785 (2021).
695 694	29	Geirsdottir, L. et al. Cross-Species Single-Cell Analysis Reveals Divergence of the Primate
695	29	Microglia Program. Cell <b>179</b> , 1609-1622 e1616, doi:10.1016/j.cell.2019.11.010 (2019).
696	30	Lafuente, E. M. <i>et al.</i> RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and
697	50	mediates Rap1-induced adhesion. <i>Developmental cell</i> <b>7</b> , 585-595,
698		doi:10.1016/j.devcel.2004.07.021 (2004).
699	31	Inagaki, T. <i>et al.</i> The retinoic acid-responsive proline-rich protein is identified in
700	21	promyeloleukemic HL-60 cells. J Biol Chem 278, 51685-51692, doi:10.1074/jbc.M308016200
700 701		(2003).
701	32	Hoffmann, F. <i>et al.</i> Prognostic and predictive value of PD-L2 DNA methylation and mRNA
702	52	expression in melanoma. Clin Epigenetics 12, 94, doi:10.1186/s13148-020-00883-9 (2020).
703	33	Chen, S. <i>et al.</i> Integrin alphaEbeta7(+) T cells direct intestinal stem cell fate decisions via
704	55	adhesion signaling. <i>Cell research</i> <b>31</b> , 1291-1307, doi:10.1038/s41422-021-00561-2 (2021).
706	34	Zhang, L. <i>et al.</i> Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in
707	54	Colon Cancer. <i>Cell</i> <b>181</b> , 442-459 e429, doi:10.1016/j.cell.2020.03.048 (2020).
708	35	Schmiedel, B. J. <i>et al.</i> Single-cell eQTL analysis of activated T cell subsets reveals activation
708	55	and cell type-dependent effects of disease-risk variants. Sci Immunol 7, eabm2508,
710		doi:10.1126/sciimmunol.abm2508 (2022).
711	36	Weiss, S. A. <i>et al.</i> Melanoma brain metastases have lower T-cell content and microvessel
712	50	density compared to matched extracranial metastases. J Neurooncol <b>152</b> , 15-25,
713		doi:10.1007/s11060-020-03619-0 (2021).
714	37	Griss, J. et al. B cells sustain inflammation and predict response to immune checkpoint
715	57	blockade in human melanoma. Nat Commun 10, 4186, doi:10.1038/s41467-019-12160-2
716		(2019).
717	38	Huang, L. et al. Correlation of tumor-infiltrating immune cells of melanoma with overall
718	50	survival by immunogenomic analysis. <i>Cancer medicine</i> <b>9</b> , 8444-8456, doi:10.1002/cam4.3466
719		(2020).
720	39	Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated
721		pathways across tissues. Nat Commun 13, 4827, doi:10.1038/s41467-022-32552-1 (2022).
722	40	Pais Ferreira, D. et al. Central memory CD8(+) T cells derive from stem-like Tcf7(hi) effector
723	70	cells in the absence of cytotoxic differentiation. <i>Immunity</i> <b>53</b> , 985-1000 e1011,
724		doi:10.1016/j.immuni.2020.09.005 (2020).
		· · · · · · · · · · · · · · · · · · ·

72541Sade-Feldman, M. et al. Defining T Cell States Associated with Response to Checkpoint726Immunotherapy in Melanoma. Cell 176, 404, doi:10.1016/j.cell.2018.12.034 (2019).

72742Connolly, K. A. et al. A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node728preserves the ongoing antitumor immune response. Sci Immunol 6, eabg7836,729doi:10.1126/sciimmunol.abg7836 (2021).

- 73043Fischer, G. M. et al. Molecular Profiling Reveals Unique Immune and Metabolic Features of731Melanoma Brain Metastases. Cancer Discov 9, 628-645, doi:10.1158/2159-8290.CD-18-1489732(2019).
- 73344Desole, C. *et al.* HGF and MET: From Brain Development to Neurological Disorders. *Front Cell*734Dev Biol **9**, 683609, doi:10.3389/fcell.2021.683609 (2021).
- 73545Zhang, Y. et al. Purification and Characterization of Progenitor and Mature Human Astrocytes736Reveals Transcriptional and Functional Differences with Mouse. Neuron 89, 37-53,737doi:10.1016/j.neuron.2015.11.013 (2016).
- 73846Zhang, Y., Jain, R. K. & Zhu, M. Recent Progress and Advances in HGF/MET-Targeted739Therapeutic Agents for Cancer Treatment. Biomedicines 3, 149-181,740doi:10.3390/biomedicines3010149 (2015).
- 74147Ramani, N. S., Morani, A. C. & Zhang, S. MET Gene High Copy Number742(Amplification/Polysomy) Identified in Melanoma for Potential Targeted Therapy. Am J Clin743Pathol 157, 502-505, doi:10.1093/ajcp/aqab171 (2022).
- 74448Rozeman, E. A. *et al.* Survival and biomarker analyses from the OpACIN-neo and OpACIN745neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 27, 256-263,746doi:10.1038/s41591-020-01211-7 (2021).
- 747 49 Reijers, I. L. M. et al. The interferon-gamma (IFN-y) signature from baseline tumor material 748 predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage 749 melanoma. Journal of Clinical Oncology 40, 9539-9539, 750 doi:10.1200/JCO.2022.40.16 suppl.9539 (2022).
- 75150Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for752interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550,753doi:10.1073/pnas.0506580102 (2005).
- 754
   51
   Gonzalez, H. *et al.* Cellular architecture of human brain metastases. *Cell* **185**, 729-745 e720,

   755
   doi:10.1016/j.cell.2021.12.043 (2022).
- 75652Dufner, A., Andjelkovic, M., Burgering, B. M., Hemmings, B. A. & Thomas, G. Protein kinase B757localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation758initiation factor 4E-binding protein 1 phosphorylation. *Mol Cell Biol* 19, 4525-4534,759doi:10.1128/MCB.19.6.4525 (1999).
- 76053Seip, K. et al. Fibroblast-induced switching to the mesenchymal-like phenotype and761PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget 7, 19997-76220015, doi:10.18632/oncotarget.7671 (2016).
- Yan, Y. *et al.* Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600
  Mutation–Positive Locally Advanced or Metastatic Melanoma from Brim7 Study.
  Annals of Oncology 25, iv378, doi:10.1093/annonc/mdu344.9 (2014).
- 76655Zhao, S. et al. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced767Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol76812, 731527, doi:10.3389/fimmu.2021.731527 (2021).
- 769 56 Quail, D. F. & Joyce, J. A. The Microenvironmental Landscape of Brain Tumors. *Cancer cell* 31,
  770 326-341, doi:10.1016/j.ccell.2017.02.009 (2017).
- 771 57 Roesler, R., Dini, S. A. & Isolan, G. R. Neuroinflammation and immunoregulation in
  772 glioblastoma and brain metastases: Recent developments in imaging approaches. *Clin Exp*773 *Immunol* 206, 314-324, doi:10.1111/cei.13668 (2021).
- 77458He, X., Guo, Y., Yu, C., Zhang, H. & Wang, S. Epithelial-mesenchymal transition is the main775way in which glioma-associated microglia/macrophages promote glioma progression. Front776Immunol 14, 1097880, doi:10.3389/fimmu.2023.1097880 (2023).

- Zhai, H., Heppner, F. L. & Tsirka, S. E. Microglia/macrophages promote glioma progression. *Glia* 59, 472-485, doi:10.1002/glia.21117 (2011).
- Sofroniew, M. V. Astrogliosis. Cold Spring Harbor perspectives in biology 7, a020420,
  doi:10.1101/cshperspect.a020420 (2014).
- 78161Herrmann, J. E. et al. STAT3 is a critical regulator of astrogliosis and scar formation after782spinal cord injury. J Neurosci 28, 7231-7243, doi:10.1523/JNEUROSCI.1709-08.2008 (2008).
- 783 62 Priego, N. *et al.* STAT3 labels a subpopulation of reactive astrocytes required for brain 784 metastasis. *Nat Med* **24**, 1024-1035, doi:10.1038/s41591-018-0044-4 (2018).
- 78563Maina, F., Hilton, M. C., Ponzetto, C., Davies, A. M. & Klein, R. Met receptor signaling is786required for sensory nerve development and HGF promotes axonal growth and survival of787sensory neurons. Genes Dev 11, 3341-3350, doi:10.1101/gad.11.24.3341 (1997).
- 78864Garcia-Diaz, A. et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2789Expression. Cell Rep 29, 3766, doi:10.1016/j.celrep.2019.11.113 (2019).
- Verhelst, J., Parthoens, E., Schepens, B., Fiers, W. & Saelens, X. Interferon-inducible protein
  Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex
  assembly. *J Virol* 86, 13445-13455, doi:10.1128/JVI.01682-12 (2012).
- 79366Acker, G. *et al.* The CXCR2/CXCL2 signalling pathway An alternative therapeutic approach in794high-grade glioma. *Eur J Cancer* **126**, 106-115, doi:10.1016/j.ejca.2019.12.005 (2020).
- Jiang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for nextgeneration sequencing paired-end reads. *BMC Bioinformatics* 15, 182, doi:10.1186/14712105-15-182 (2014).
- 79868Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for799RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186/s13059-014-0550-8 (2014).
- 80069Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are801coordinately downregulated in human diabetes. Nat Genet 34, 267-273, doi:10.1038/ng1180802(2003).
- 80370Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray804and RNA-seq data. BMC Bioinformatics 14, 7, doi:10.1186/1471-2105-14-7 (2013).
- 80571Biermann, J. et al. Dissecting the treatment-naive ecosystem of human melanoma brain806metastasis. Cell 185, 2591-2608 e2530, doi:10.1016/j.cell.2022.06.007 (2022).
- 80772Schildhaus, H. U. et al. MET amplification status in therapy-naive adeno- and squamous cell808carcinomas of the lung. Clin Cancer Res 21, 907-915, doi:10.1158/1078-0432.CCR-14-0450809(2015).
- 81073Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time811quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408,812doi:10.1006/meth.2001.1262 (2001).
- 813
- 814
- 815
- 816

## 818 **Figure legends**

Figure 1: Transcriptome and methylome profiling of Iba1<sup>high</sup> and Iba1<sup>neg</sup> MBM revealed 819 820 identification of subset-specific genes. a.) Immunohistochemistry (IHC) for Iba1 (red) of MBM of indicated patients. b.) Representative IHC for levels of CD3 in Iba1<sup>high</sup> (Pat 4) and 821 822 Iba1<sup>neg</sup> (Pat 1) MBM. c.) Immune score of MBM (study EGAS00001005976, n=16) indicating 823 different immunologic (color coded) subsets of tumors. d.) Dot plot showing the significant 824 correlation of Iba1/AIF1 expression and immune score of brain metastases (BM, R=0.86, 825 p<2.2e-16) and extracranial metastases (EM, R=0.78, p=5.5e-13). e.) Survival analysis of 826 patients with MBM (study, EGAS00001003672), featuring high or low level of Iba1/AIF1 827 expression revealed no significant difference (p=0.11). f.) Survival analysis of TCGA 828 melanoma patients (n=459), featuring high or low level of Iba1/AIF1 expression revealed 829 significant difference (logrank p=1.3e-07) and Cox-regression analysis showed association 830 with favorable disease course (HR=0.46). g.) Schematic representation of candidate 831 identification by methylome and transcriptome profiling of n=16 MBM of study. Methylome (850k) profiling of Iba1<sup>high</sup> (n=5) or Iba1<sup>neg</sup> (n=2) identified 416 differentially methylated 832 833 regions (DMRs), within the 5'-UTR of 316 corresponding genes of which 296 were expressed in MBM with 56 genes (77 DMRs), significantly (p≤0.05) discriminating Iba1<sup>high</sup> 834 and Iba1<sup>low/neg</sup> MBM. h.) Heat map representation of 77 DMRs (left panel) and top expressed 835 836 (right panel) genes (n=31). Analysis identified a panel of 12 genes that clustered with 837 expression of microglia/TAM-associated genes AIF1, SYK and HCK. i.) Correlation analysis 838 of cluster genes with association to immune/TAM regulated processes, strength of 839 correlation is color coded. j.) Comparative t-SNE representation of brain cell subclasses 840 microglia, neurons and oligodendrocytes (left) and expression of APBB1IP (Amyloid Beta 841 Precursor Protein Binding Family B Member 1 Interacting Protein), expression level (log2) 842 RPKM) is color coded. k.) Dot plot showing the significant correlation of APBB1IP expression 843 and immune score of brain metastases (BM, R=0.86, p<2.2e-16) and extracranial

metastases (EM, R=0.92, p<2.2e-16). Significance was determined by unpaired, two-sided t-</li>
test (d, g, k).

Figure 2: Expression of ITGB7 serves as indicator of lymphocyte infiltration. a.) Box 846 847 plot representation of levels of ITGB7 indicates a wide pattern of expression among indicated 848 immune cell populations. Monocytes and neutrophil granulocytes show low levels of ITGB7. 849 b.) IHC of a representative MBM of a patient with refractory intracranial disease for lba1 (red, 850 first column) and CD3 (brown, second column) indicating focal enrichment of 851 microglia/macrophages and CD3<sup>+</sup> T cells within ITGB7 positive areas (red, second column). 852 Hematoxylin and eosin (H&E) staining shows discrimination of tumor cells and tumor-853 infiltrating lymphocytes (TILs) c.) Expression (FPKM, log2) of CD4, PD-L1 (CD274) and 854 SUSD3 in MBM with high or low level of ITGB7, indicating cellular co-occurrence. d.) Dot plot 855 showing the significant inverse correlation (R=-0.87, p=5.2e-05) of  $\beta$ -values (probe 856 cg26689077) indicating the methylation level at a side located within the proximal enhancer-857 like structure of the ITGB7 gene and immune score of MBM (n=14) of study 858 EGAS00001005976 (first panel). Box plots represent a significant (p=4.5e-04) or non-859 significant (p=0.86) association of ITGB7 methylation (probe cg26689077) or BRAF mutation 860 status (center and right panels) of all MBM investigated (n=21). e.) Dot plot showing the 861 significant correlation of ITGB7 expression and immune score of MBM (R=0.51, p=1.8e-06) 862 and EM (R=0.61, p=1.1e-09) indicating immune-related expression of ITGB7 irrespective of 863 the side of metastasis. f.) Correlation map showing high association (p<0.05) of ITGB7 with 864 relevant immune cell markers such as PD-1 (PDCD1), PD-L1 (CD274), PD-L2 (PDCD1LG2) 865 but low correlation with tumor cell markers NGFR, MITF, MLANA or SLC45A2. g.) Dot plot 866 showing the significant correlation of ITGB7 and expression of PD-L2 (BM: R=0.45, p=3.4e-867 05; EM: R=0.42, p=1.1e-03) and SUSD3 (BM: R=0.44, p=5.2e-05; EM: R=0.61, p=2.6e-07). 868 h.) Dot plot showing the correlation of ITGB7 expression and immune score of primary (PT; R=0.59, p=9.4e-16), metastatic (EM; R=0.78, p=2.2e-16) and brain metastatic (BM; R=0.2, 869 870 p=0.61) melanoma (TCGA-SKCM), indicating that expression of ITGB7 is independent from 871 melanoma progression stages. i.) Survival analysis of TCGA melanoma patients (n=459), 29

featuring high or low level of ITGB7 and SUSD3 expression revealed significant difference (logrank p=4.0e-04 and p=6.6e-08) and Cox-regression analysis showed association with favorable disease course (HR=0.60 and HR=0.48). Box and whisker plots show median (center line), the upper and lower quartiles (the box), and the range of the data (the whiskers), including outliers (a, c, d). Significance was determined by unpaired, two-sided ttest (c, d) or one-way ANOVA (a).

878 Figure 3: Signature-based deconvolution identified parameter of MBM featuring a 879 favorable disease course and identified a role of MET signaling. a.) Single-sample 880 GSEA (ssGSEA)-based deconvolution of MBM of study EGAS00001005976 using 881 customized gene signatures indicating "Signaling" processes, cellular subsets and stages of 882 microglia and astrocyte and immune cell subsets. ssGSEA demonstrated distinct separation 883 of MBM with high, median or low immune score regarding expression levels of signature 884 genes, BMCs served as controls. ssGSEA uncovered differentially activated pathways and 885 processes such as MET and STAT3 and interferon signaling, senescence (SenMayo), stress 886 response and tumor inflammation in tumors enriched for reactive microglia and astrocytes 887 and innate and acquired immune cells subsets. b.) Confocal microscopy images of orthotopic 888 tumors established by stereotactic injection of BMC1-M4 or BMC2 cells into brains of Crl:CD1-Foxn1<sup>nu</sup> mice<sup>23</sup>, stained for Iba1 (green, microglia) or Iba1, GFAP (red, astrocytes) 889 890 and KBA.62 (turquoise, pan-melanoma cell marker). DAPI served as nuclear dye. Markers 891 show distinct areas of tumor (MBM) and microenvironment (TME) and regions of microglia infiltration, 21 days after intracranial injection<sup>23</sup>. MBM-TME boarders are indicated by white, 892 893 dashed lines. c.) IHC of tumors investigated in (a) for activation and tyrosine phosphorylation (residue Y705) of STAT3. pSTAT3<sup>Y705</sup> is particularly present in microenvironmental cells 894 895 (astrocytes). Black, dashed lines indicate MBM-TME boarders. In b, c, bars indicate 50 µm. 896 d-e.) Expression levels of hepatocyte growth factor (HGF) in tumors of studies 897 EGAS00001005976, TCGA-SKCM and EGAS00001003672 demonstrating HGF expression 898 in all tumor subsets. f-g.) Investigation of HGF expression in immune cell subsets (DICE database<sup>35</sup>) and brain cells (study GSE73721) revealed highest levels in basophil 899 30

900 granulocytes and monocytes (f) and in astrocytes and microglia (g). h.) UMAP projection of 901 expression profiles from nuclei isolated from 5 neurotypical donors as provided by Seattle 902 Alzheimer's disease brain cell atlas (https://portal.brain-map.org/explore/seattle-alzheimers-903 disease), cellular subtypes are color coded (left panel). Log-normalized expression levels of 904 HGF in nuclei isolated from 5 neurotypical donors (center panel). Log-normalized expression 905 levels of HGF in nuclei isolated from 84 aged donors (42 cognitively normal and 42 with 906 dementia), right panel, demonstrating increased number of HGF expressing microglia and 907 astrocytes as triggered by inflammatory processes. i.) Dot plot showing the correlation of 908 HGF expression and immune score of BM (R=0.49, p=5.3e-06) and EM (R=0.41, p=1.5e-03) 909 indicating a potential role of HGF in immune cell-related processes. Box and whisker plots 910 show median (center line), the upper and lower quartiles (the box), and the range of the data 911 (the whiskers), including outliers (d-g). Significance was determined by unpaired, two-sided t-912 test (e) or one-way ANOVA (g).

913 Figure 4: Ecad<sup>+</sup> MBM are defined by expression of MET receptor. a.) Schematic 914 summary of the initial screen of MBM expression data of our recent study 915 (EGAS00001005976; n=16 MBM) for subset expressed receptors. MBM contain Ecad<sup>+</sup> and 916 NGFR<sup>+</sup> subsets and admixed cells such reactive microglia, labeled by expression of 917 Iba1/AIF1 and or P2RY12. The initial survey yielded 24 receptors that potentially establish 918 cell survival/growth of MBM. b.) Correlation map (Spearman, p<0.05) showing the 919 relationship of identified receptors expressed in MBM of our previous study, emphasizing the 920 distinct pattern of Ecad<sup>+</sup> and NGFR<sup>+</sup> molecular subsets. The value of the correlation 921 coefficient is color coded. c.) Box plots depicting the levels of most relevant receptors that significantly separated Ecad<sup>high</sup> and Ecad<sup>low</sup> subsets of MBM and extracerebral metastases 922 923 (EM) of study EGAS00001003672, providing MBM = 79, EM = 59 (ADIPOR1, Adiponectin 924 Receptor 1, p=0.019/7.9e-05; SIRPA, Signal Regulatory Protein Alpha, p=1.1e-05/0.0046; PLXNC1, Plexin C1, p=4.6e-06/3e-04). d.) Box plots depicting the levels of MET in Ecad<sup>high</sup> 925 and Ecad<sup>low</sup> subsets of MBM and EM (left panel, p=1.4e-04/p=0.41) or in all subtypes of 926 927 MBM and EM (p=2.7e-05) in high and low proliferating tumor cell subsets (right panel,

928 p=9.1e-03). e.) IHC of selected MBM for MET and MITF validated the two subsets. f-g.) Expression and activation status of MET in BRAF wildtype (wt; Pts 14, 39) and BRAF<sup>V600E/R</sup> 929 930 mutated MBM (Pts 28, 29, 31). Phosphorylation of MET at residues Y1234/1235 is critical for kinase activation. h.) IHC of indicated tumors for co-localization of pMET<sup>Y1234/1235</sup> (brown) and 931 932 Iba1 (red) demonstrating potential activation of MET receptor signaling tumor cells by stromal 933 cell-secreted HGF. i.) Heat map representing expression levels of regulators and targets of 934 interferon signaling and immune related genes showing clustering according to the level of 935 ITGB7 expression. Box and whisker plots show median (center line), the upper and lower 936 quartiles (the box), and the range of the data (the whiskers), including outliers (c, d). 937 Significance was determined by unpaired, two-sided t-test (c, d).

938 Figure 5: Inhibitors of MET receptor decrease growth of brain metastatic and 939 conventional melanoma cell lines. a.) Comparative IHC of selected MBM for levels of 940 phosphorylated and activated MET receptor (pMET<sup>Y1234/1235</sup>) and ribosomal protein S6 (pS6<sup>235/236</sup>) of consecutive sections suggesting MET-associated activation of mTOR 941 942 signaling. b.) Immunofluorescence microscopy of lymph node-metastatic (T2002) and brain 943 metastatic (BMC53) patient-derived melanoma cell lines for co-occurrence of MET (red) and pS6<sup>235/236</sup> (green). DAPI served as nuclear dye. c.) qPCR analysis of BMCs for expression of 944 945 MET receptor, bars indicate median levels ±SD of three biological replicates. d.) Gross initial 946 ARQ197 sensitivity test of BMC53 and BMC1-M1 cells showing high and low levels of MET 947 expression. Cell density was determined by crystal violet staining. e.) Broad range 948 determination of sensitivity of BMCs, T2002 and conventional melanoma cell lines (A375, 949 A2058, MeWo) to METi PHA-665752 and ARQ197. Cell density and BRAF mutation status 950 are indicated. Dotted line depicts the estimated range of IC<sub>50</sub>. f.) PHA-665752 dose-response 951 fit curve-based calculation of IC<sub>50</sub> values of A375 cells with overexpression of NGFR or RFP 952 control cells and MeWo cells. g.) Dabrafenib dose-response fit curve-based calculation of IC<sub>50</sub> values of BMCs exhibiting different BRAF mutations (BMC2<sup>p.N581Y</sup>, BMC4<sup>p.V600K</sup>) and 953 A375<sup>p.V600E</sup>, A2058<sup>p.V600E</sup> cells. h-i.) Live cell imaging-based tracking of confluence (%) of 954 955 BMC2 and BMC4 cells in dependence of increasing doses of ARQ197. Shown are median 32

956 values±SD of eight technical replicates. A representative out of two experiments is shown. j.) 957 ARQ197 dose-response fit curves of BMCs, T2002 and conventional cell lines. Calculated 958 IC<sub>50</sub> values are indicated, suggesting response of dabrafenib resistant cell lines to METi. k.) 959 Bar diagram summarizing IC<sub>50</sub> values (nM) indicating the response of indicated cell lines to 960 ARQ197. The BRAF status is color coded. I.) Working model suggesting the activation of 961 MET receptor signaling in adjacent tumor cells and in (reactive) microglia (RM) by microglia 962 released HGF. IRF-mediated HGF expression in turn is triggered by immune cell 963 (monocytes/macrophages, M) released interferon-gamma. HGF binding to tumor cell (TC) 964 expressed MET receptor directs downstream activation of the RAS/RAF/MEK/ERK and the 965 PI3K/AKT/mTOR/p70S6K branch. The latter is leading to phosphorylation and activation of 966 the ribosomal protein S6. Box and whisker plots show median (center line), the upper and 967 lower quartiles (the box), and the range of the data (the whiskers), including outliers (c).

Figure 6: HGF/MET receptor signaling might be activated in tumor cells at immune cell/TAM dense areas. Schematic representation of our working model suggesting the interaction of tumor cells with stromal cells, particularly microglia and immune cells, consequentially leading to activation of MET signaling in tumor cells via stromal cell-released HGF. Expression of HGF in turn and ITGB7 and PD-L1 is likely triggered by T cell provided interferon-gamma. Increased levels of ITGB7 may foster recruitment of immune cells.

974

975

976

- 977
- 978

979

## 981 Supplementary figure legends

982 Supplementary figure 1: Iba1/AIF1 expression separates MBM a.) Immunofluorescence (IF) for Iba1 (red) and GFAP (labeling of reactive and normal astrocytes) of a NRAS Q61R 983 984 mutated MBM (Pat 15) that progressed on treatment with immune checkpoint inhibitors (ICi; 985 ipilimumab) showed strong infiltration of tumor-associated microglia/macrophages (TAMs) 986 and the presence of aggregates of microglia and reactive astrocytes. MBM (without adjacent 987 stromal cells) of Pat 3 showed high infiltration of TAMs. DAPI served as nuclear dye. b.) Box 988 plots representing the levels (FPKM, log2) of Iba1/AIF1 in MBM and BMC of study 989 EGAS00001005976 and MBM and EM of study EGAS00001003672. c.) Per sample 990 representation of expression levels (FPKM, log2) of Iba1/AIF1 in MBM, brain metastases-991 derived cell lines (BMCs) and brain controls (BC) of studies mentioned in (b). d-f.) Survival 992 analyses of MBM patients (n=67) of study EGAS00001003672 or of TCGA-SKCM study 993 (n=459), featuring high or low level of APBB1IP (d, e) or PD-L2 (PDCD1LG2) expression. 994 Analysis revealed a significant (logrank p=5.5e-07) favorable disease course (HR=0.50, Coxregression analysis) of APBB1IP<sup>high</sup> melanoma (e) and favorable outcome associated with 995 996 high levels of PD-L2 expression in MBM (f). Survival of MBM patients was not significantly 997 affected by APBB1IP levels (d). g.-m.) Correlation and cell type-specificity of microglia 998 markers SYK, HCK, P2RY12 and AIF1. n.) Dot plot shows significant (R=0.85, p=1.3e-04) 999 correlation of ITGB7 expression of MBM (n=16, study EGAS00001005976) and immune score. Box and whisker plots show median (center line), the upper and lower quartiles (the 1000 1001 box), and the range of the data (the whiskers), including outliers (b).

1002

Supplementary figure 2: The indicators of favorable disease course ITGB7, SUSD3 and APBB1IP are broadly expressed among immune cell subsets. a.) Box plots showing expression levels of ITGB7 among T cell subsets (CD4, T helper cells), CD8 (cytotoxic T cells), NK cells (natural killer cells), cDC (conventional dendritic cells), pDC (plasmacytoid dendritic cells) lymphoid follicle-residing B cells (FollicularB cell subsets), innate lymphoid

1008 cells, type 3 (ILC3), mast cells, macrophages (Macro), monocyte subsets (Mono), myofibrils 1009 (non-immune related cells), plasma cells (PlasmaB) and tumor-associated macrophages 1010 (TAMs) as provided by study GSE146771. b.) IHC of MBM of indicated patients for ITGB7. 1011 ITGB7 expression is evident in lymphocyte-enriched areas. c.-d.) Boxplot showing 1012 expression levels of SUSD3 in immune cell subsets of (a), and shows levels obtained from 1013 DICE (Database of Immune Cell Expression, Expression quantitative trait loci (eQTLs) and 1014 Epigenomics), suggesting broad but variable expression among immune cell subsets. e.) 1015 Comparative illustration of levels of ITGB7 and SUSD3 as requested from DICE. f.) Box plot 1016 showing expression levels of APBB1IP among immune cell subsets of the aforementioned 1017 GEO study, suggesting a broad expression among immune cell types. Box and whisker plots 1018 show median (center line), the upper and lower quartiles (the box), and the range of the data 1019 (the whiskers), including outliers (a, c, d, f).

1020

1021 Supplementary figure 3: Methylome profiling uncovered epigenetic regulatory sites in the ITGB7 gene. a.) Schematic representation of the ITGB7 gene, showing exons, intronic 1022 1023 regions and sites of epigenetic marks as depicted by indicated probes. ITGB7 expression 1024 levels are associated with methylation at sites covered by probes cg26689077 and 1025 cg01033299 located within a proximal enhancer-like signature and intronic region close to 5'-1026 UTR. Additional regions as covered by probes cg18320160 and cg11510999 are associated 1027 with the BRAF mutation status of tumors. b.-c.) Dot plots showing no significant correlation 1028 of methylation status (indicated by  $\beta$ -values) at sites covered by probes cg18320160 and 1029 cg11510999 and immune score. d.-e.) Box pots indicating a significant association of  $\beta$ -1030 values, determined by aforementioned probes (cg11510999, p = 3e-06; cg18320160, p=0.003) and BRAF status (BRAF<sup>V600</sup> vs. wt/NRAS<sup>Q61</sup>) of MBM. Box and whisker plots show 1031 1032 median (center line), the upper and lower quartiles (the box), and the range of the 1033 data (the whiskers), including outliers (d, e).

1035 Supplementary figure 4: Single sample GSEA revealed classification of immune 1036 molecular subtypes of MBM. a.) Single-sample GSEA (ssGSEA)-based deconvolution of 1037 MBM (n=79) of study EGAS00001003672 using customized gene signatures indicating 1038 "Signaling" processes, cellular subsets and stages of microglia and astrocyte and immune 1039 cell subsets. ssGSEA demonstrated distinct separation of MBM with high, median or low 1040 immunescore regarding expression levels of signature genes, BMCs served as controls. 1041 ssGSEA uncovered differentially activated pathways and processes such as MET and 1042 STAT3 and interferon signaling, senescence (SenMayo), stress response and tumor 1043 inflammation in tumors enriched for reactive microglia and astrocytes and innate and 1044 acquired immune cells subsets. b.) Boxplot showing expression levels of HGF in indicated 1045 immune cell subsets obtained from DICE. c.-e.) Expression of MET receptor pathway genes 1046 in MBM of study EGAS00001003672 showing high or low enrichment of microglia, as 1047 determined by levels of microglia-specific genes (SYK, HCK, AIF1/lba1= microglia score 1048 suggests a significant correlation of microglia infiltration and activation of MET receptor 1049 signaling. HGF, hepatocyte growth factor (p=1.8e-09); PIK3CG, Phosphatidylinositol-4,5-1050 Bisphosphate 3-Kinase Catalytic Subunit Gamma (p<2.2e-16); PTK2B, Protein Tyrosine 1051 Kinase 2 Beta (p<2.2e-16); STAT3, Signal Transducer And Activator Of Transcription 3 1052 (p=5.3e-11); MAP4K1; Mitogen-Activated Protein Kinase Kinase Kinase 1 (p=3.4e-1053 12). Box and whisker plots show median (center line), the upper and lower quartiles (the 1054 box), and the range of the data (the whiskers), including outliers (b-e).

1055 Supplementary figure 5: MET-FISH analysis revealed absence of MET receptor 1056 amplifications in MBM. a.) Hematoxylin and eosin (H&E) staining shows tumor cell 1057 histology (upper row). Fluorescence in-situ hybridization with a MET-specific probe (red) 1058 revealed no specific amplifications of the MET gene in MBM (n=7) as compared with 1059 centromere control (green) and irrespective of the BRAF/NRAS mutation status. DAPI served 1060 as nuclear dye, bars indicate 50 µm. b.) Quantitative representation of FISH analysis, 1061 indicating the number of MET copies per nucleus and ratio of MET and CEP7 (Centromer 7). c.) IHC for Iba1 (red) and pMET<sup>Y1234/1235</sup> (brown) revealed absence of activated MET in 1062 36

1063 Iba1<sup>high</sup> microglia residing in adjacent tissue (upper panel) and MET activation in tumor cells 1064 without neighboring TAMs. d.) HGF expression in brain cells residing within the different 1065 lobes (FL, frontal; PL, parietal; TL, temporal; OL, occipital lobe) and pons as retrieved from 1066 the Allan Brain Atlas (<u>https://portal.brain-map.org/</u>). Box and whisker plots show median 1067 (center line), the upper and lower quartiles (the box), and the range of the data (the 1068 whiskers), including outliers (d).


1069

1070 Supplementary figure 6: Expression of interferon-related genes is enriched in MBM of ITGB7<sup>high</sup>/IScore<sup>high</sup> phenotype. a.) Heat map indicating expression levels and subset-1071 1072 association of interferon-inducible genes, mediators of interferon signaling and relevant 1073 immune cell-expressed markers such as CD3E, CD4, CD8A in MBM (n=79) of study 1074 EGAS00001003672. Molecular subsets, category of genes and strength of expression are 1075 color coded. b.-d.) Dot plots indicating the significant correlation of ITGB7, IRF1 (Interferon 1076 Regulatory Factor 1), IRF8 and IFNG in MBM and EM of the aforementioned study. e.) Dot 1077 plots indicating the significant correlation of expression of HGF, IRF1 and IRF8 in MBM and 1078 EM of the aforementioned study. f.-g.) Investigation of expression data of murine BV2 1079 microglia cells (study GSE132739) following interferon (1 U/mL IFNy, 24h) or control treatment revealed interferon-responsible genes. Interferon treatment significantly increased 1080 1081 levels of ltgb7 (p=2.9e-03), Hgf (p=4.4e-02), Mx1 (p=1.2e-02), Cd274 (p=3.6e-02), Irf1 1082 (p=3.1e-02), Cxcl9 (p=4.0e-03) and Aif1 (p=4.0e-03). However, Susd3 was significantly 1083 downregulated upon interferon treatment (p=4.0e-02). h.) ssGSEA analysis of MBM with 1084 defined signatures showing enrichment of interferon-related signaling among other indicated processes. Box and whisker plots show median (center line), the upper and lower quartiles 1085 1086 (the box), and the range of the data (the whiskers), including outliers (f, g).


1087


1088 **Supplementary figure 7: The mTOR/pS6 signaling is activated in MBM.** a.) IHC of MBM 1089 (Pat 14) for levels of activated/phosphorylated MET receptor (pMET<sup>Y1234/1235</sup>) and mTOR/pS6 1090 (pS6<sup>S235/236</sup>) signaling revealed co-occurrence of both. b.) Co-occurrence of pS6<sup>S235/236</sup> and


- 1091 MITF. Bars indicate 50 µm. c.) Confocal microscopy imaging of BMC1-M1 and BMC53 cells
- 1092 for levels of NGFR and MET showing a mutually exclusive expression pattern or low level of
- 1093 MET in NGFR<sup>+</sup> cells. d.) Live cell imaging tracked dose-response of BMC1-M1 cells to
- 1094 increasing doses of ARQ197.



Redmer et al., Figure 1









Time


Time


Redmer et al., Figure 2




Redmer et al., Figure 3









Redmer et al., Figure 4






BM

BW





а

## Interferon-induced HGF stimulates MET signaling in MBM

